Piroxicam Ir Dc Granules 6.58% W/W Pellets

What are Piroxicam Ir Dc Granules 6.58% W/W Pellets?

Piroxicam Ir Dc Granules 6.58% W/W Pellets are a pharmaceutical pellet formulation containing piroxicam at a specified drug loading of 6.58% w/w. Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) used in appropriate medicinal formulations for pain and inflammatory conditions. The precise formulation characteristics, processing suitability and release performance should be verified against the product’s technical documentation.

Uses / Applications

Piroxicam Ir Dc Granules 6.58% W/W Pellets may be considered for pharmaceutical formulation and further processing, subject to confirmation of the supplied material’s intended application.

Potential considerations include:

• Incorporation into a suitable pharmaceutical dosage form, where supported by formulation specifications.

• Use as a pharmaceutical intermediate in a validated manufacturing process.

• Development of a finished medicinal product with a defined piroxicam dose, subject to applicable formulation and quality requirements.

Therapeutic context: Piroxicam is an NSAID that reduces pain and inflammation by inhibiting prostaglandin synthesis. The therapeutic indications of a finished medicine depend on its approved product information. The pellets should not be assumed suitable for direct administration.

6. Benefits

Potential formulation-related considerations include:

• Specified drug loading: The supplied strength is 6.58% w/w.

• Identifiable active ingredient: Piroxicam is the stated active ingredient.

• Formulation development: The material may be assessed for use in an appropriate pharmaceutical manufacturing process.

• Technical evaluation: Product specifications and supporting documentation can help the receiving manufacturer determine suitability.

Pellet uniformity, particle size, dissolution performance, stability and manufacturing compatibility must be established through product-specific documentation and testing.

7. Side Effects

As the supplied product is described as pharmaceutical pellets, its suitability for direct patient administration has not been established.

Patient-level adverse effects cannot be determined from the pellet dosage form and drug loading alone. Safety depends on the final medicinal formulation, dose, route of administration and approved product information.

Piroxicam-containing medicines can cause adverse effects, including gastrointestinal irritation, ulceration or bleeding, kidney-related complications, fluid retention and hypersensitivity reactions. Serious cardiovascular and gastrointestinal risks may also occur. These risks should be assessed using the applicable information for the finished medicinal product.

8. How Does It Work?

Formulation mechanism: The supplied name indicates IR DC granules. The precise pellet structure, excipients and drug-release performance have not been provided, so a specific release mechanism cannot be confirmed.

Pharmacological mechanism: Piroxicam inhibits cyclo-oxygenase (COX) enzymes, reducing the production of prostaglandins involved in pain and inflammation. This pharmacological action relates to the active ingredient and does not independently establish the performance of the supplied pellet formulation.

9. Dosage Guidelines / Processing Instructions

For pharmaceutical processing, the incorporation level should be calculated using the confirmed drug loading, target dose and approved formulation specifications.

• Confirm the assay and drug-loading basis against the applicable technical documentation.

• Establish the required quantity through formulation calculations and validated manufacturing procedures.

• Verify processing compatibility, content uniformity and finished-product performance through appropriate quality-control testing.

• Do not assume the pellets can be swallowed directly or incorporated into a dosage form without further evaluation.

No processing quantities, temperatures, mixing times or manufacturing parameters are specified because supporting technical information has not been supplied.

For patient use, follow the approved information for the finished medicinal product and the recommendation of a qualified healthcare professional.

10. When Not to Use

The pellets should not be used in a formulation unless their identity, quality, intended application and suitability have been confirmed.

For finished medicines containing piroxicam, contraindications may include:

• Known hypersensitivity to piroxicam or relevant ingredients.

• A history of NSAID-associated gastrointestinal bleeding or perforation.

• Active peptic ulceration or gastrointestinal bleeding.

• Certain severe kidney, liver or heart conditions, according to the applicable product information.

• Specific circumstances involving pregnancy, particularly late pregnancy, where piroxicam use may be contraindicated.

These are considerations for piroxicam-containing medicinal products, not blanket contraindications for handling a pharmaceutical intermediate. Refer to the approved product information for the finished medicine.

11. Drug / Product Interactions

For pharmaceutical intermediates, compatibility with other active ingredients and excipients must be established through formulation development and appropriate technical assessment.

For finished medicines containing piroxicam, clinically relevant interactions may involve:

• Anticoagulants and antiplatelet medicines, which can increase bleeding risk.

• Other NSAIDs, including aspirin at analgesic doses, which may increase adverse effects.

• Corticosteroids, which may increase gastrointestinal complications.

• Certain diuretics and antihypertensive medicines, whose effects may be affected by NSAIDs.

• Lithium and methotrexate, for which concentrations or toxicity may increase.

• Other medicines that affect kidney function.

These interactions should be assessed using the approved information for the finished medicinal product. They do not establish compatibility or incompatibility during pharmaceutical manufacturing.

12. Safety Advice

• Handle the material according to its applicable safety data sheet and technical documentation.

• Follow the receiving manufacturer’s procedures for pharmaceutical material handling.

• Use appropriate occupational precautions based on the active ingredient and the documented exposure risks.

• Avoid unnecessary dust generation and exposure during handling.

• Maintain material identification, traceability and quality-control records.

• Do not use the material for patient administration unless its intended use and suitability are specifically established.

13. General Instructions

• Verify the product name and stated drug loading before use.

• Check the batch identification and applicable manufacturing, expiry or retest information.

• Inspect the packaging for damage, contamination or evidence of tampering.

• Review the certificate of analysis and technical specifications when available.

• Confirm that the material meets the receiving manufacturer’s requirements.

• Follow the documented handling, processing and storage instructions.

• Retain appropriate quality-control and traceability records.

14. Special Dietary / Lifestyle Tips

Dietary and lifestyle advice is generally not applicable to pharmaceutical pellets intended for further processing.

Any dietary restrictions or lifestyle recommendations depend on the final medicinal product, its approved indications and the patient’s clinical circumstances. The supplied pellets should not be treated as a medicine for direct consumption without appropriate confirmation.

15. Comparison with Other Formulations

No formulation can be considered universally superior. Selection depends on the intended dosage form, validated manufacturing process and product-specific performance data.

16. Precautions & Warnings

• Confirm the meaning of “IR DC” against the supplier’s technical specifications before making detailed formulation claims.

• Verify the drug-loading basis and applicable quality requirements before manufacturing.

• Do not assume a specific coating, particle-size range or dissolution profile.

• Confirm suitability for the intended finished dosage form through appropriate development and quality-control procedures.

• Follow documented storage and handling requirements.

• Assess piroxicam-specific occupational and clinical safety considerations using reliable product documentation.

17. Can I Use It With Other Medicines or Ingredients?

Compatibility with other active ingredients and excipients cannot be established from the product name and drug loading alone.

Before combining Piroxicam Ir Dc Granules 6.58% W/W Pellets with other materials, the receiving manufacturer should evaluate:

• Physical and chemical compatibility.

• Potential effects on assay, content uniformity and stability.

• The effect of processing on the active ingredient.

• The finished formulation’s release characteristics and quality requirements.

Clinical use of piroxicam alongside other medicines is a separate consideration and must follow the approved prescribing information.

18. Storage

Store according to the manufacturer’s approved product specifications and technical documentation. Refer to the product packaging or applicable technical data sheet for the required storage conditions.

19. Frequently Asked Questions (FAQs)

1. What are Piroxicam Ir Dc Granules 6.58% W/W Pellets?

They are a pharmaceutical pellet product identified as containing piroxicam at a stated drug loading of 6.58% w/w. Additional formulation characteristics require confirmation.

2. What is the active ingredient?

The stated active ingredient is piroxicam, a non-steroidal anti-inflammatory drug.

3. What does 6.58% W/W mean?

It indicates a stated weight-by-weight proportion of 6.58%. The exact assay basis and interpretation should be verified against the supplier’s approved specification.

4. Are these pellets intended for direct administration?

Direct administration suitability has not been established. Their intended use should be confirmed through the applicable product documentation.

5. Do these pellets have an immediate-release profile?

The supplied product name includes “IR”, which indicates immediate release. However, the actual release performance and relevant specifications should be verified before publication of a definitive technical claim.

6. What packing options are available?

Packing details have not been provided. Packaging information can be requested from Kelar Pharmachem India and confirmed for the specific supply requirement.

7. Is a technical data sheet available?

The technical data sheet is available upon request, subject to confirmation of the applicable product documentation.

8. Can this product be sourced for pharmaceutical export?

Kelar Pharmachem India operates as a pharmaceutical sourcing and export company. Product availability, destination-market requirements, documentation and supply terms should be confirmed for the specific enquiry.